147 related articles for article (PubMed ID: 26786269)
1. Dynamics and modulation studies of human voltage gated Kv1.5 channel.
Bhuyan R; Seal A
J Biomol Struct Dyn; 2017 Feb; 35(2):380-398. PubMed ID: 26786269
[TBL] [Abstract][Full Text] [Related]
2. Ligand binding to the voltage-gated Kv1.5 potassium channel in the open state--docking and computer simulations of a homology model.
Andér M; Luzhkov VB; Aqvist J
Biophys J; 2008 Feb; 94(3):820-31. PubMed ID: 17905851
[TBL] [Abstract][Full Text] [Related]
3. Modeling the binding modes of Kv1.5 potassium channel and blockers.
Yang Q; Du L; Wang X; Li M; You Q
J Mol Graph Model; 2008 Sep; 27(2):178-87. PubMed ID: 18485768
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of hesperetin on Kv1.5 potassium channels stably expressed in HEK 293 cells and ultra-rapid delayed rectifier K(+) current in human atrial myocytes.
Wang H; Wang HF; Wang C; Chen YF; Ma R; Xiang JZ; Du XL; Tang Q
Eur J Pharmacol; 2016 Oct; 789():98-108. PubMed ID: 27397430
[TBL] [Abstract][Full Text] [Related]
5. Molecular basis for Kv1.5 channel block: conservation of drug binding sites among voltage-gated K+ channels.
Decher N; Pirard B; Bundis F; Peukert S; Baringhaus KH; Busch AE; Steinmeyer K; Sanguinetti MC
J Biol Chem; 2004 Jan; 279(1):394-400. PubMed ID: 14578345
[TBL] [Abstract][Full Text] [Related]
6. Revealing kinetics and state-dependent binding properties of I
Ellinwood N; Dobrev D; Morotti S; Grandi E
Chaos; 2017 Sep; 27(9):093918. PubMed ID: 28964116
[TBL] [Abstract][Full Text] [Related]
7. Interactions of Propofol With Human Voltage-gated Kv1.5 Channel Determined by Docking Simulation and Mutagenesis Analyses.
Kojima A; Fukushima Y; Ito Y; Ding WG; Ueda R; Seto T; Kitagawa H; Matsuura H
J Cardiovasc Pharmacol; 2018 Jan; 71(1):10-18. PubMed ID: 29283926
[TBL] [Abstract][Full Text] [Related]
8. Novel, potent inhibitors of human Kv1.5 K+ channels and ultrarapidly activating delayed rectifier potassium current.
Lagrutta A; Wang J; Fermini B; Salata JJ
J Pharmacol Exp Ther; 2006 Jun; 317(3):1054-63. PubMed ID: 16522807
[TBL] [Abstract][Full Text] [Related]
9. High-throughput analysis of drug binding interactions for the human cardiac channel, Kv1.5.
Karczewski J; Kiss L; Kane SA; Koblan KS; Lynch RJ; Spencer RH
Biochem Pharmacol; 2009 Jan; 77(2):177-85. PubMed ID: 18955031
[TBL] [Abstract][Full Text] [Related]
10. Kv1.5 is an important component of repolarizing K+ current in canine atrial myocytes.
Fedida D; Eldstrom J; Hesketh JC; Lamorgese M; Castel L; Steele DF; Van Wagoner DR
Circ Res; 2003 Oct; 93(8):744-51. PubMed ID: 14500335
[TBL] [Abstract][Full Text] [Related]
11. Interaction of propofol with voltage-gated human Kv1.5 channel through specific amino acids within the pore region.
Kojima A; Ito Y; Ding WG; Kitagawa H; Matsuura H
Eur J Pharmacol; 2015 Oct; 764():622-632. PubMed ID: 26256861
[TBL] [Abstract][Full Text] [Related]
12. Effects of flecainide, quinidine, and 4-aminopyridine on transient outward and ultrarapid delayed rectifier currents in human atrial myocytes.
Wang Z; Fermini B; Nattel S
J Pharmacol Exp Ther; 1995 Jan; 272(1):184-96. PubMed ID: 7815332
[TBL] [Abstract][Full Text] [Related]
13. Identification of Verapamil Binding Sites Within Human Kv1.5 Channel Using Mutagenesis and Docking Simulation.
Ding WG; Tano A; Mi X; Kojima A; Seto T; Matsuura H
Cell Physiol Biochem; 2019; 52(2):302-314. PubMed ID: 30816676
[TBL] [Abstract][Full Text] [Related]
14. Molecular dynamics of Kv1.3 ion channel and structural basis of its inhibition by scorpion toxin-OSK1 derivatives.
Bhuyan R; Seal A
Biophys Chem; 2015; 203-204():1-11. PubMed ID: 26001067
[TBL] [Abstract][Full Text] [Related]
15. Modeling of high-affinity binding of the novel atrial anti-arrhythmic agent, vernakalant, to Kv1.5 channels.
Eldstrom J; Fedida D
J Mol Graph Model; 2009 Oct; 28(3):226-35. PubMed ID: 19713139
[TBL] [Abstract][Full Text] [Related]
16. Identification, synthesis, and activity of novel blockers of the voltage-gated potassium channel Kv1.5.
Peukert S; Brendel J; Pirard B; Brüggemann A; Below P; Kleemann HW; Hemmerle H; Schmidt W
J Med Chem; 2003 Feb; 46(4):486-98. PubMed ID: 12570371
[TBL] [Abstract][Full Text] [Related]
17. Open channel block of Kv1.5 channels by HMQ1611.
Dong C; Li J; Ding W; Ueda R; Xie X; Wu J; Matsuura H; Horie M
Front Pharmacol; 2022; 13():965086. PubMed ID: 36188606
[TBL] [Abstract][Full Text] [Related]
18. The molecular basis of high-affinity binding of the antiarrhythmic compound vernakalant (RSD1235) to Kv1.5 channels.
Eldstrom J; Wang Z; Xu H; Pourrier M; Ezrin A; Gibson K; Fedida D
Mol Pharmacol; 2007 Dec; 72(6):1522-34. PubMed ID: 17872968
[TBL] [Abstract][Full Text] [Related]
19. Voltage- and time-dependent block by perhexiline of K+ currents in human atrium and in cells expressing a Kv1.5-type cloned channel.
Rampe D; Wang Z; Fermini B; Wible B; Dage RC; Nattel S
J Pharmacol Exp Ther; 1995 Jul; 274(1):444-9. PubMed ID: 7616429
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology of voltage-gated potassium channel Kv1.5--impact on cardiac excitability.
Wettwer E; Terlau H
Curr Opin Pharmacol; 2014 Apr; 15():115-21. PubMed ID: 24632326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
